Denali Therapeutics Inc. Deferred Tax Assets, Tax Credit Carryforwards
Denali Therapeutics Inc. (DNLI) had Deferred Tax Assets, Tax Credit Carryforwards of $155.33 million as of 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsTaxCreditCarryforwards · last filed 2026-02-26
- 2025-12-31: Deferred Tax Assets, Tax Credit Carryforwards $155.33M.
- 2024-12-31: Deferred Tax Assets, Tax Credit Carryforwards $124.92M.
- 2023-12-31: Deferred Tax Assets, Tax Credit Carryforwards $95.81M.
- 2022-12-31: Deferred Tax Assets, Tax Credit Carryforwards $69.56M.
| Period end | Deferred Tax Assets, Tax Credit Carryforwards |
|---|---|
| 2025-12-31 | $155.33M 10-K · filed 2026-02-26 |
| 2024-12-31 | $124.92M 10-K · filed 2026-02-26 |
| 2023-12-31 | $95.81M 10-K · filed 2025-02-27 |
| 2022-12-31 | $69.56M 10-K · filed 2024-02-28 |
| 2021-12-31 | $48.06M 10-K · filed 2023-02-27 |
| 2020-12-31 | $27.41M 10-K · filed 2022-02-28 |
| 2019-12-31 | $19.13M 10-K · filed 2021-02-26 |
| 2018-12-31 | $9.56M 10-K · filed 2020-02-27 |
| 2017-12-31 | $4.07M 10-K · filed 2019-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |